Showing 1831-1840 of 2038 results for "".
- Bausch + Lomb Launches Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipeshttps://modernod.com/news/bausch-lomb-launches-biotrue-hydration-boost-lubricant-eye-drops-and-biotrue-micellar-eyelid-cleansing-wipes/2479359/Bausch + Lomb announced the US launch of Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipes. Both products are preservative-free and formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes. “One of the majo
- ScienceBased Health Announces New Ophthalmology Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-announces-new-ophthalmology-clinical-advisory-panel/2479314/ScienceBased Health (SBH) announced the formation of its new Ophthalmology Clinical Advisory Panel that will provide insight and recommendations on eye care industry trends and new developments. In addition, it will help guide and support the company’s educational initiatives in the ophthalmology
- Alcon’s ORA System Reaches 2 Million Caseshttps://modernod.com/news/alcons-ora-system-reaches-2-million-cases/2479303/Alcon announced its Optiwave Refractive Analysis (ORA) intraoperative aberrometer system has reached 2 million cases worldwide. This milestone signifies an important leap forward in cataract surgery by delivering greater accuracy than preoperative calculation methods alone. The ORA Syste
- Lenz Therapeutics Debuts with $47 Million Series A Financinghttps://modernod.com/news/lenz-therapeutics-debuts-with-47-million-series-a-financing/2479301/Lenz Therapeutics debuted today with a $47 million Series A financing to move the company’s lead asset, an eyedrop formulation of aceclidine, toward an NDA submission for the treatment of presbyopia. The financing was
- The Retina Center, of Minneapolis and St. Paul, Joins Retina Consultants of Americahttps://modernod.com/news/the-retina-center-of-minneapolis-and-st-paul-joins-retina-consultants-of-america/2479299/Retina Consultants of America (RCA) announced that a 12th practice, The Retina Center, in Minneapolis and St. Paul, Minnesota, has joined RCA. The addition of The Retina Center expands RCA’s presence in Minnesota, as they join forces with RCA’s existing partner in the region, Vitreoret
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- Retinal Consultants of San Antonio Joins Retina Consultants of Americahttps://modernod.com/news/retinal-consultants-of-san-antonio-joins-retina-consultants-of-america/2479269/Retinal Consultants of San Antonio has joined the Retina Consultants of America (RCA), the management services organization’s its 11th practice. The addition of Retinal Consultants of San Antonio bolsters RCA’s presence in Texas as they join forces with RCA’s existing partner pra
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Eyenovia Announces Topline Results From VISION-1 Phase 3 Study of MicroLine for the Treatment of Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia/2479241/Eyenovia announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for the temporary improvement of near vision in adults with presbyopia, achieved its primary endpoint. Preparations are underway for a second phase 3 registration study, VISION-2. T